Pharmacological treatment of depression during pregnancy;L'impiego dei farmaci antidepressivi in gravidanza

Recenti Progressi in Medicina

Volumn 97, Issue 2, 2006, Pages 94-107

  Bellantuono, Cesario ^a   Migliarese, Giovanni ^a   Imperadore, Giuseppe ^b  

^a Sezione di Psichiatria e Psicologia Clinica   (Italy)

^b Azienda Ospedaliera   (Italy)

Author keywords

Antidepressant drugs; Anxiety disorders; Depression; Neonatal toxicity; Neurobehavioral impairment; Pregnancy; SSRIs; Teratogenesis

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; EJACULATION DISORDER; FETUS GROWTH; HAND TREMOR; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; INSOMNIA; MEMORY DISORDER; MICTURITION DISORDER; MOOD DISORDER; NAUSEA; NERVOUSNESS; NEWBORN DISEASE; ORTHOSTATIC HYPOTENSION; PREGNANCY; PREMATURE LABOR; PRURITUS; PSYCHOMOTOR DISORDER; RASH; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SPONTANEOUS ABORTION; TERATOGENESIS; TREMOR; VERTIGO; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; ITALY; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS; TERATOGENS;

EID: 33644991622     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Bellantuono C, Balestrieri M. Gli antidepressivi: profile farmacologico-clinico. In: Trattato di Psicofarmacologia. Il Pensiero Scientifico Editore: Roma 2003.
2. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293-306.
3. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 2003; 37: 641-656.
4. Fricchione G. Clinical practice. Generalized anxiety disorder. N Engl J Med 2004; 351: 675-682.
5. Schruers K, Koning K, Luermans J, Haack MJ, Griez E. Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 2005; 111: 261-271.
6. Otto MW, Smits JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 2004; 65 suppl 5: 34-41.
7. Scott J. Cognitive therapy for depression. Br Med Bull 2001; 57: 101-113.
8. Haddad PM. Do antidepressants cause dependence? Epidemiol Psichiatr Soc 2005; 14: 58-62.
9. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004 (suppl): 21-27.
10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
11. Paykel ES, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005; 15: 411-423.
12. Andersson L, Sundstrom-Poromaa I, Bixo M, Wulff M, Bondestam K, Strom M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003; 189: 148-154.
13. Heron J, O'Connor TG, Evans J, Golding J, Glover V. The course of anxiety and depression through pregnancy and the postpartum in a community sample. J Affect Disord 2004; 80: 65-73.
14. Josefsson A, Berg G, Nordin C, Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251-255.
15. O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43: 569-573.
16. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257-260.
17. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698-709.
18. Gotlib IH, Whiffen VE, Mount JH, Milne K, Cordy NI. Prevalence rates and demographic characteristics associated with depression in pregnancy and the post-partum. J Consult Clin Psychol 1989; 57: 269-274.
19. O'Hara MW. Depression during pregnancy. In: Post-partum depression. New York Springer Verlag 1994: 110-120.
20. Einarson A, Selby P, Koren G. Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Beware of the risks of abrupt discontinuation. Can Fam Physician 2001; 47: 489-490.
21. Cohen LS, Nonacs RM, Bailey JW, Viguera AC, Reminick AM, Altshuler LL, et al. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Women Ment Health 2004.
22. Cohen LS, Altshuler LL, Stowe ZN, Faraone SV. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment. A preliminary retrospective study. Psychother Psychosom 2004; 73: 255-258.
23. Smith MV, Rosenheck RA, Cavaleri MA, Howell HB, Poschman K, Yonkers KA. Screening for and detection of depression, panic disorder, and PTSD in public-sector obstetric clinics. Psychiatr Serv 2004; 55: 407-414.
24. George DT, Ladenheim JA, Nutt DJ. Effect of pregnancy on panic attacks. Am J Psychiatry 1987; 144: 1078-1079.
25. Cowley DS, Roy-Byrne PP. Panic disorder during pregnancy. J Psychosom Obstet Gynaecol 1989; 10: 193-210.
26. Klein DF, Skrobala AM, Garfinkel RS. Preliminary look at the effects of pregnancy on the course of panic disorder. Anxiety 1994; 1: 227-232.
27. Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. Postpartum course in women with preexisting panic disorder. J Clin Psychiatry 1994; 55: 289-292.
28. Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry 1994; 55: 539-542.
29. Sutter-Dallay AL, Giaconne-Marcesche V, Glatigny-Dallay E, Verdoux H. Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. Eur Psychiatry 2004; 19: 459-463.
30. Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry 1997; 58: 330-334; quiz 335-336.
31. Buttolph ML, Holland A. Obsessive-compulsive disorder in pregnancy and childbirth. In: Jenike MA, Baer L, Minichiello WE eds. Obsessive-compulsive disorder: theory and management. Chicago: Year Book Medical 1990: 89-97.
32. Maina G, Albert U, Bogetto F, Vaschetto P, Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999; 89: 49-58.
33. Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. J Anxiety Disord 2003; 17: 461-478.
34. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165-171.
35. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45: 1093-1099.
36. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 726-735.
37. Misri S, Oberlander TF, Fairbrother N, Carter D, Ryan D, Kuan AJ, et al. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry 2004; 49: 684-689.
38. Diego MA, Field T, Hernandez-Reif M, Cullen C, Schanberg S, Kuhn C. Prepartum, postpartum, and chronic depression effects on newborns. Psychiatry 2004; 67: 63-80.
39. Dawson G, Klinger LG, Panagiotides H, Hill D, Spieker S. Frontal lobe activity and affective behavior of infants of mothers with depressive symptoms. Child Dev 1992; 63: 725-737.
40. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162: 79-91.
41. Andersson L, Sundstrom-Poromaa I, Wulff M, Astrom M, Bixo M. Neonatal outcome following maternal antenatal depression and anxiety: a population-based study. Am J Epidemiol 2004; 159: 872-881.
42. Rahman A, Iqbal Z, Bunn J, Lovel H, Harrington R. Impact of maternal depression on infant nutritional status and illness: a cohort study. Arch Gen Psychiatry 2004; 61: 946-952.
43. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95: 487-490.
44. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107-1111.
45. Hedegaard M, Henriksen TB, Sabroe S, Secher NJ. Psychological distress in pregnancy and preterm delivery. BMJ 1993; 307: 234-239.
46. Mulder EJ, Robles de Medina PG, Huizink AC, Van den Bergh BR, Buitelaar JK, Visser GH. Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev 2002; 70: 3-14.
47. Glover V, O'Connor TG. Effects of antenatal stress and anxiety: implications for development and psychiatry. Br J Psychiatry 2002; 180: 389-391.
48. Van den Bergh BR, Mulder EJ, Mennes M, Glover V. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 2005; 29: 237-258.
49. O'Connor TG, Heron J, Glover V. Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry 2002; 41: 1470-1477.
50. O'Connor TG, Heron J, Golding J, Beveridge M, Glover V. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children. Br J Psychiatry 2002; 180: 502-508.
51. Laplante DP, Barr RG, Brunet A, Galbaud du Fort G, Meaney ML, Saucier JF, et al. Stress during pregnancy affects general intellectual and language functioning in human toddlers. Pediatr Res 2004; 56: 400-410.
52. Weinstock M. Alterations induced by gestational stress in brain morphology and behaviour of the offspring. Prog Neurobiol 2001; 65: 427-451.
53. Teixeira JM, Fisk NM, Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study. BMJ 1999; 318: 153-157.
54. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-1138.
55. Arredondo de Arreola G, Rodriguez-Bonito R, Trevino-Alanis MG, Arreola-Arredondo B, Astudillo-Castillo G, Russildi JM. [Congenital malformations in live-born neonates]. Bol Med Hosp Infant Mex 1990; 47: 822-827.
56. Swain S, Agrawal A, Bhatia BD. Congenital malformations at birth. Indian Pediatr 1994; 31: 1187-1191.
57. Fabro SE. Clinical obstetrics. New York: John Wiley 1987.
58. Vorhees CV, Brunner RL, Butcher RE. Psychotropic drugs as behavioral teratogens. Science 1979; 205: 1220-1225
59. Ali SF, Buelke-Sam J, Newport GD, Slikker W, Jr. Early neurobehavioral and neurochemical alterations in rats prenatally exposed to imipramine. Neurotoxicology 1986; 7: 365-380.
60. Costa LG, Steardo L, Cuomo V. Structural effects and neurofunctional sequelae of developmental exposure to psycho therapeutic drugs: experimental and clinical aspects. Pharmacol Rev 2004; 56: 103-147.
61. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-262.
62. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889-1895.
63. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 2000; 23: 245-253.
64. Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002; 63 suppl 7: 24-30.
65. Kuenssberg EV, Knox JD. Imipramine in pregnancy. Br Med J 1972; 2: 292.
66. Idanpaan-Heikkila J, Saxen L. Possible teratogenicity of imipramine-chloropyramine. Lancet 1973; 2: 282-284.
67. Golden SM, Perman KI. Bilateral clinical anophthalmia: drugs as potential factors. South Med J 1980; 73: 1404-1407.
68. Cohen LS, Altshuler LL. Pharmacological management of psychiatric illness during pregnancy and postpartum period. Psychiatr Clin North Am 1997; 4: 21-60.
69. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606.
70. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci 1997; 22: 192-196.
71. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-2061.
72. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17: 255-261.
73. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-316.
74. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973; 2: 318-319.
75. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29: 479-484.
76. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J 1982; 284: 1837-1838.
77. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980; 97: 308-310.
78. Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972; 81: 570-572.
79. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365: 482-487.
80. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015.
81. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996-1000.
82. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713-718.
83. Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996; 53: 304-308.
84. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000; 30: 89-94.
85. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503-508.
86. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-610.
87. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 812-815.
88. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14: 823-827.
89. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-2248.
90. Sunder K, Wisner KL. Antidepressants and premature labor. Am J Psychiatry 2004; 161: 925-926.
91. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993; 92: 721-722.
92. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288-291.
93. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720-726.
94. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65: 230-237.
95. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402-408.
96. Oberlander TF, Eckstein Grunau R, Fitzgerald C, Ellwood AL, Misri S, Rurak D, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002; 51: 443-453.
97. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 2003; 26: 547-562.
98. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728-1730.
99. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28: 137-152.
100. Biswas PN, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J Psychopharmacol 2003; 17: 121-126.
101. Nonacs R, Cohen L, Viguera A, Mogielnicki J. Diagnosis and treatment of mood and anxiety disorders in pregnancy. Washington: American Psychiatric Publishing 2005: 17-51.
102. de Moor RA, Mourad L, ter Haar J, Egberts AC. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]. Ned Tijdschr Geneeskd 2003; 147: 1370-1372.
103. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004; 19: 235-238.
104. Scholle SH, Haskett RF, Hanusa BH, Pincus HA, Kupfer DJ. Addressing depression in obstetrics/gynecology practice. Gen Hosp Psychiatry 2003; 25: 83-90.
105. Bellantuono C, Imperadore G. Gli psicofarmaci in gravidanza e nell'allattamento. Roma: Il Pensiero Scientifico Editore 2005.